The global hypercalcemia treatment market to lead the market during forecast period with market valuation of US$ 10,696.6 Mn in 2018.

1. Coherent Market Insights
Market Research and Business Consulting Services
https://www.coherentmarketinsights.com/
COVID-19 Impact Tracker

2. HYPERCALCEMIA TREATMENT MARKET
ANALYSIS
Hypercalcemia Treatment Market,By Drug Type
(Bisphosphonates (Clodronate, Etidronate, Ibandronate,
Pamidronate, Zoledronic, Acid), Calcitonin, Glucocorticoids,
Denosumab, Calcimimetics), By Distribution Channel
(Hospitals, Clinics, Independent Pharmacy & Drug Stores), and
By Region (North America, Latin America, Europe, Asia Pacific,
Middle East & Africa) - Size, Share, Outlook, and Opportunity
Analysis, 2019 - 2027

3. The global hypercalcemia treatment market is estimated to account
for US$ 10,696.6 Mn in terms of value in 2018 and is expected to
reach US$ 28,060.0 Mn by the end of 2028.
Drivers
• High incidence of hypercalcemia is a major factor boosting growth
of the global hypercalcemia treatment market.For instance,in the
study,‘Incidence of hypocalcemia and hypercalcemia in
hospitalized patients: Is it changing?’, published in the Journal of
Clinical and Translational Endocrinology,in September 2018,
researchers found that 27.72% of the study patients suffered from
hypocalcemia and 4.74% from hypercalcemia. Moreover, 585
cases of hypercalcemia were detected.
• Moreover,increasing prevalence of cancer is also expected to aid
in growth of the market. For instance, according to the World
Health Organization, around 18.1 million new cases and 9.6
million deaths were registered due to cancer worldwide in 2018.

4. • Moreover, favorable reimbursement scenario is also
expected to aid in growth of the market. Reimbursements
enable lesser out-of-pocket costs of treatment for patients,
despite having a low income eligibility.For instance, Amgen
has a reimbursement policy on its XGEVA (denosumab
injection), in which the company pays the out-of-pocket
amount in excess of US$ 25 per dose; up to US$ 10,000 in
assistance per calendar year. Approximately 70% of XGEVA
patients with commercial or Medicare coverage incurred
US$ 0 out-of-pocket cost due to favorable reimbursement
policy offered by Amgen,Inc.
• North America region held dominant position in the global
hypercalcemia treatment market in 2018, accounting for
45.5% share in terms of value, followed by Europe.

6. Market Opportunities
• Product innovations in hypercalcemia drug types other than
bisphosphonates is expected to offer lucrative growth
opportunities for players in the global hypercalcemia treatment
market.Bisphosphonate is the single largest product being utilized
for hypercalcemia treatment.End users have recognized the
bisphosphonate therapy as effective.Still,the global hypercalcemia
treatment market is yet to witness major product innovations in
the product types of calcitonin, calcimimetics,and glucocorticoids.
• Improving systems for recognizing hypercalcemia can aid in
addressing common causes for delayed diagnosis and treatment
of the disease,thereby aiding in growth of the market.Educating
patients and providers about the consequences of untreated
disease can also help in this regard.

7. • Bisphosphonates segment in the global hypercalcemia
treatment market was valued at US$ 7,306.2 Mn in 2018
and is expected to reach US$ 19,798.3 Mn by 2027 at a
CAGR of 11.7% during the forecast period.

8. Market Trends
• R&D in the treatment of hypercalcemia is augmenting
growth of the market. For instance,in July 2019, researchers
from Ascendis Pharma A/S, in their study, ‘Design and
Preclinical Development of TransCon PTH, an Investigational
Sustained?Release PTH Replacement Therapy for
Hypoparathyroidism,’ reported that TransCon PTH can be
used to normalize blood levels of calcium and phosphate.
• Sarcoidosis,a complex disease with no known cause, is
linked with hypercalcemia.The study,“Hypercalcemic
pancreatitis a rare presentation of sarcoidosis: A case
report,” published in the journal Medicine in January 2018,
reported a sarcoidosis patient with pancreatitis —
inflammation of the pancreas — and hypercalcemia.

9. Competitive Section
Major players operating in the global hypercalcemia
treatment market include, Bayer Pharma AG, Sun
Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen
Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Cipla Inc., and
XOMA Corporation.

10. Key Developments
Players in the market are focused on attending
various conferences to expand their customer
base.For instance, in October 2019, XOMA
Corporation presented at the 2019 Cantor Fitzgerald
Global Healthcare Conference held in New York.

11. • Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
Reference:
https://www.coherentmarketinsights.com/market-
insight/hypercalcemia-treatment-market-3504

12. About Us
Coherent Market Insights is a global market intelligence and
consulting organization focused on assisting our plethora of
clients achieve transformational growth by helping them make
critical business decisions.
What we provide:
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

13. Contact Us
Mr. Shah
Coherent Market Insights Pvt.Ltd.
Address: 1001 4th Ave, #3200 Seattle, WA 98154,
U.S.
Phone: +1-206-701-6702
Email: sales@coherentmarketinsights.com

14. Thank You!
Kindly follow CMI Social Media Profiles for the latest
company updates
Facebook
Linkedin
Twitter
https://www.coherentmarketinsights.com/